TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
https://doi.org/10.14412/1995-4484-2011-61
Abstract
Objective: to study the time course of rituximab therapy-induced changes in the synovial fluid levels of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), interleukins (IL) 1β and 6, and tumor necrosis factor-α (TNF-α) in patients with rheumatoid arthritis (RA).
Results and discussion. The synovial fluid levels of IL-1ß, IL-6, TNF-α, OPG, and RANKL were studied in 54 RA patients who were seropositive for rheumatoid factor and cyclic citrullinated peptide. Differences were found in the levels of the study cytokines in patients with a varying duration of the disease.
Conclusion. Rituximab was observed to be highly effective in correcting cytokine parameters in early RA.
Results and discussion. The synovial fluid levels of IL-1ß, IL-6, TNF-α, OPG, and RANKL were studied in 54 RA patients who were seropositive for rheumatoid factor and cyclic citrullinated peptide. Differences were found in the levels of the study cytokines in patients with a varying duration of the disease.
Conclusion. Rituximab was observed to be highly effective in correcting cytokine parameters in early RA.
References
1. <div><p>Насонов Е.Л. Ревматоидный артрит как общемедицинская проблема. Терапевт 2004;5:5-7.</p><p>Насонов Е.Л., Чичасова Н.В. Рациональная терапия ревматоидного артрита. М., 2010;223 с. Насонов Е.Л., Каратеев Д.Е. и др. Современные стандарты фармакотерапии ревматоидного артрита. Клин фармакол и тер 2005;14(1):72-5.</p><p>Потанин Т.К. Ревматоидный артрит. Новые данные о старой болезни. М., 2007;68 с.</p><p>Шостак Н.А., Тимофеев В.Т. Кардиоваскулярные нарушения и остеопороз у больных ревматоидным артритом. Здоровье Украины 2009;24:26-8.</p><p>Prevoo M.L.L., van HoffA., Kuper H.H. Modified disease activity scores that include twenty-eight-joint counts. Arthr Rheum 1995;38:44-52.</p><p>Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonists mechanisms of actions: a comprehensive review. Pharmacol Ther 2008;117:244-79.</p><p>Бадокин В.В. Избранные лекции по клинической ревматологии. Под ред. В.А. Насоновой, Н.В. Бунчука. М., 2003;82-90.</p><p>Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of IMPACT 2 trial. Ann Rheum Dis 2005;64:197-200.</p><p>Насонова В.А. Ревматология. М.: Медицина, 2008;457 с.</p><p>Pettit A.R., Walsh N.C., Manning C. et al. RANKL protein is expressed at the pannusbone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 2006;45:1068-76.</p><p>Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии. 2-е изд., доп. М.: Практическая медицина, 2009;302 с</p><p>Lee C.K., Lee E.Y., Chung S.M. Effects of disease modifying anthirheumatic drags and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor Kappa B ligand. Arthr Rheum 2004;50(12):3831-43.</p><p>Насонов Е.Л. Применение ингибиторов фактора некроза опухоли при РА: место этанерцепта. Науч-практич ревматол 2008; 5:1-20</p></div><br />
Review
For citations:
Bezgin A.V., Knyazeva L.A. TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT. Rheumatology Science and Practice. 2011;49(4):44-46. (In Russ.) https://doi.org/10.14412/1995-4484-2011-61
Views:
947
Email this article 